The clinicopathological spectrum and driver mutation profile in classic BCR-ABL1 negative myeloproliferative neoplasms: a three-year study from a tertiary care center in Kerala, South India
DOI:
https://doi.org/10.18203/2320-6012.ijrms20240217Keywords:
Myeloproliferative neoplasms, BCR-ABL1 negative, Polycythaemia vera, Primary myelofibrosis, Essential thrombocythemia, Driver mutationsAbstract
Background: Myeloproliferative neoplasms (MPNs) are clonal hematopoietic stem cell disorders primarily of the adults. The 2016 World Health Organization (WHO) classification of MPNs include the molecular landscape as one of the diagnostic criteria. JAK2 exon14 (JAK2 V617F), JAK2 exon12, Myeloproliferative leukemia virus oncogene exon 10 (MPL 515), and calreticulin exon 9 (CALR) mutations are the main somatic driver mutations detected in classic BCR-ABL1 negative MPNs.
Methods: A retrospective, cross-sectional study was conducted including 99 patients diagnosed with classic BCR-ABL1 negative MPNs during a 3-year time period, from March 2018 to February 2021 in the departments of pathology and clinical haematology- haemato oncology of a tertiary care teaching hospital. Clinical, haematological and morphological features were analysed and correlated with MPN associated mutation studies done in blood/bone marrow samples.
Results: The prevalence of polycythaemia vera (PV) was found to be higher than other MPN, two third of which were JAK2 positive. More than half of the cases of primary myelofibrosis (PMF) and essential thrombocythemia (ET) also showed JAK2 mutation. CALR was positive in 17.4% of ET and 31.3% of PMF; MPL in 4.4% of ET and 3.1% of PMF.
Conclusions: The prevalence of triple-negative MPN point towards the need for whole-exome sequencing of triple-negative MPN.
References
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision of World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-405.
Ferreira Cristina S, Polo B, Lacerda JF. Somatic Mutations in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms. Semin Hematol. 2018;55(4):215-22.
Yassin MA, Taher A, Mathews V, Hou HA, Shamsi T, Tuğlular TF et al. MERGE: A Multinational, Multicenter Observational Registry for Myeloproliferative Neoplasms in Asia, including Middle East, Turkey, and Algeria. Cancer Med. 2020;9(13):4512-26.
Kaifie A, Kirschner M, Wolf D, Maintz C, Hänel M, Gattermann N, et al. Study Alliance Leukemia (SAL). Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry. J Hematol Oncol. 2016;9:18.
Alvarez-Larrán A, Pérez-Encinas M, Ferrer-Marín F, Hernández-Boluda JC, Ramírez MJ, Martínez-López J, et al. Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea. Haematological. 2017;102(1):103-9.
Barbui T, Thiele J, Gisslinger H, Finazzi G, Carobbio A, Tefferi A, et al. Masked polycythemia vera (mPV): results of an international study. Am J Hematol. 2014;89(1):52-4.
Dixith, Roopa, Sara, A, Vangala, Navatha, Uppin, Shantveer G et al. Clinicopathological spectrum of BCR-ABL-Negative myeloproliferative neoplasms with correlation with janus-Associated kinase 2 mutation. Indian J Med Paediatric Oncol. 2019;40(1):35.
Sazawal S, Bajaj J, Chikkara S, Jain S, Bhargava R, Mahapatra M, et al. Prevalence of JAK2 V617F mutation in Indian patients with chronic myeloproliferative disorders. Indian J Med Res. 2010;132:423-7.
Maddali M, Kulkarni UP, Ravindra N, Arunachalam AK, Venkatraman A, Lionel S, et al. Mutation profile in BCR-ABL1-negative myeloproliferative neoplasms: A single-center experience from India. Hematol Oncol Stem Cell Ther. 2021;19:S1658.
Singh S, Kaur K, Paul D, Jain K, Singh J, Narang V, Garg B, Sood N, Dhillon B. Clinical and Molecular Attributes of Patients with BCR/ABL1-negative Myeloproliferative Neoplasms in India: Real-world Data and Challenges. Clin Lymphoma Myeloma Leuk. 2021;21(6):e569-78.
Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27(9):1874-81.
Tefferi A, Wassie EA, Lasho TL, Finke C, Belachew AA, Ketterling RP et al. Calreticulin mutations and long-term survival in essential thrombocythemia. Leukemia. 2014;28(12):2300-3.
Tefferi A, Lasho TL, Jimma T, Finke CM, Gangat N, Vaidya R et al. One thousand patients with primary myelofibrosis: the mayo clinic experience. Mayo Clin Proc. 2012;87(1):25-33.
Ferreira Cristina S, Polo B, Lacerda JF. Somatic Mutations in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms. Semin Hematol. 2018;55(4):215-22.
